20 assets in Acute Promyelocytic Leukemia

Therapeutic assets addressing Acute Promyelocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Promyelocytic Leukemia	Associazione Italiana Ematologia Oncologia Pediatrica	P4	A (82)
Tretinoin Acute Promyelocytic Leukemia	The Affiliated People's Hospital of Ningbo University	P4	A (82)
Arsenic Trioxide Acute Promyelocytic Leukemia	Quetzal Therapeutics	P4	BBB (79)
Daunomycin Acute Promyelocytic Leukemia	Peking University People's Hospital	P4	BBB (74)
Cyclophosphamide Acute Promyelocytic Leukemia	Sumithira Vasu	P3	BBB (72)
Etoposide Acute Promyelocytic Leukemia	Peking University People's Hospital	P2	BBB (72)
Nivestim Acute Promyelocytic Leukemia	Associazione Italiana Ematologia Oncologia Pediatrica	P3	BB (70)
Realgar-Indigo Naturalis Formulation Acute Promyelocytic Leukemia	Instituto do Cancer do Estado de São Paulo	P3	BB (66)
Qtx-2101 Acute Promyelocytic Leukemia	Quetzal Therapeutics	P3	B (60)
Gemtuzumab Ozogamicin Acute Promyelocytic Leukemia	Wake Forest University Health Sciences	P2	B (57)
Lisaftoclax Acute Promyelocytic Leukemia	The Affiliated People's Hospital of Ningbo University	P2/3	B (57)
Venetoclax Acute Promyelocytic Leukemia	Anhui Medical University	P2/3	B (57)
Mylotarg Acute Promyelocytic Leukemia	Associazione Italiana Ematologia Oncologia Pediatrica	P2	CCC (53)
Marble Dust Acute Promyelocytic Leukemia	SDK Therapeutics, Inc.	P1	CC (46)
sy-2101 Acute Promyelocytic Leukemia	Syros Pharmaceuticals	P1	CC (43)
Turalio Acute Promyelocytic Leukemia	National Cancer Institute (NCI)	P1	CC (43)